# US 8,278,105 B2 · Induction, propagation and isolation of liver progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,105 B2
- Document ID: US8278105B2
- Status: Granted
- Kind: B2
- Application number: 12/556,478
- Filed: 2009-09-09
- Published: 2010-03-11
- Granted: 2012-10-02
- Earliest claimed: 2008-09-09
- Assignees: University of Southern California
- Inventors: Martin F. Pera; Tracy L. Zinberg; Kouichi Hasegawa
- Web page: https://patentgrep.com/patent/US8278105B2

## CPC

- C12N 5/0672: {Stem cells; Progenitor cells; Precursor cells; Oval cells}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/70: Enzymes
- C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N 2506/02: from embryonic cells
- C12N 2533/92: Amnion; Decellularised dermis or mucosa
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of induction and isolation of progenitor cells from stem cell cultures, specifically liver progenitor cells from human embryonic stem cell cultures. In one embodiment, the present invention provides a method of inducing hepatocyte-like progenitor cells by placing a quantity of human embryonic stem cells in a medium supplemented with an inhibitor of the MAPK/MEK/ERK signaling pathway, FGFR, GSK3 and/or BMP.

## Claims

### Claim 1

A method of inducing human hepatocyte cells from human embryonic stem cells, comprising:
a) providing a quantity of human embryonic stem (hES) cells;
b) placing the hES cells on an extracellular matrix and in a medium containing one of:
i) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, and CHIR99021,
ii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, CHIR99021 and dorsomorphin, or
iii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, PD0325901, CHIR99021, and dorsomorphin; and
c) culturing the hES cells to form hepatocyte cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the medium containing
i) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, and CHIR99021, comprises a concentration of about 1 to about 6 μM SU5402.

### Claim 3 (depends on 2)

The method of claim 2, wherein the SU5402 is about 2 μM.

### Claim 4 (depends on 1)

The method of claim 1, wherein the medium containing
i) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, and CHIR99021, comprises a concentration of about 0.2 to about 3.0 μM PD184352.

### Claim 5 (depends on 4)

The method of claim 4, wherein the PD184352 is about 0.8 μM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the medium containing
i) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, and CHIR99021, comprises a concentration of about 1 to about 6 μM CHIR99021.

### Claim 7 (depends on 6)

The method of claim 6, wherein the CHIR99021 is about 3 μM.

### Claim 8 (depends on 1)

The method of claim 1, wherein the medium containing
ii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, CHIR99021 and dorsomorphin, comprises a concentration of about 1 to about 6 μM SU5402.

### Claim 9 (depends on 8)

The method of claim 8, wherein the SU5402 is about 2 μM.

### Claim 10 (depends on 1)

The method of claim 1, wherein the medium containing
ii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, CHIR99021 and dorsomorphin, comprises a concentration of about 0.2 to about 3.0 μM PD184352.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PD184352 is about 0.8 μM.

### Claim 12 (depends on 1)

The method of claim 1, wherein the medium containing
ii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, CHIR99021 and dorsomorphin, comprises a concentration of about 1 to about 6 μM CHIR99021.

### Claim 13 (depends on 12)

The method of claim 12, wherein the CHIR99021 is about 3 μM.

### Claim 14 (depends on 1)

The method of claim 1, wherein the medium containing
ii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, SU5402, PD184352, CHIR99021 and dorsomorphin, comprises a concentration of about 1 to about 6 μM dorsomophin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the dorsomorphin is about 3 μM.

### Claim 16 (depends on 1)

The method of claim 1, wherein the medium containing
iii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, PD0325901, CHIR99021, and dorsomorphin; comprises a concentration of about 0.2 to about 3.0 μM PD0325901.

### Claim 17 (depends on 16)

The method of claim 16, wherein the PD0325901 is about 0.8 μM.

### Claim 18 (depends on 1)

The method of claim 1, wherein the medium containing
iii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, PD0325901, CHIR99021, and dorsomorphin comprises a concentration of about 1 to about 6 μM CHIR99021.

### Claim 19 (depends on 18)

The method of claim 18, wherein the CHIR99021 is about 3 μM.

### Claim 20 (depends on 1)

The method of claim 1, wherein the medium containing
iii) neurobasal medium, DMEM, N2, B27, L-glutamine, β-ME, PD0325901, CHIR99021, and dorsomorphin comprises a concentration of about 1 to about 6 μM dorsomophin.

### Claim 21 (depends on 20)

The method of claim 20, wherein the dorsomophin is about 3 μM.
